Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Guy Amit; Amit Rosen; Avraham B. Wagshal; Dan Y. Bonneh; Tzvika Liss; Aviva Grosbard; Reuven Ilia; Amos Katz

doi:10.1016/j.amjcard.2004.02.071

Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Guy Amit, Amit Rosen, Avraham B. Wagshal, Dan Y. Bonneh, Tzvika Liss, Aviva Grosbard, Reuven Ilia, Amos Katz

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.

Original language	English
Pages (from-to)	1558-1560
Number of pages	3
Journal	American Journal of Cardiology
Volume	93
Issue number	12
DOIs	https://doi.org/10.1016/j.amjcard.2004.02.071
State	Published - 15 Jun 2004

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2004.02.071

Cite this

@article{cb89ca6e4e4342ec8d6f1a9ddc4a8015,

title = "Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation",

abstract = "The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.",

author = "Guy Amit and Amit Rosen and Wagshal, {Avraham B.} and Bonneh, {Dan Y.} and Tzvika Liss and Aviva Grosbard and Reuven Ilia and Amos Katz",

note = "Funding Information: This study was supported by a grant from Teva Pharmaceuticals L.T.D., Israel. ",

year = "2004",

month = jun,

day = "15",

doi = "10.1016/j.amjcard.2004.02.071",

language = "English",

volume = "93",

pages = "1558--1560",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

AU - Amit, Guy

AU - Rosen, Amit

AU - Wagshal, Avraham B.

AU - Bonneh, Dan Y.

AU - Liss, Tzvika

AU - Grosbard, Aviva

AU - Ilia, Reuven

AU - Katz, Amos

N1 - Funding Information: This study was supported by a grant from Teva Pharmaceuticals L.T.D., Israel.

PY - 2004/6/15

Y1 - 2004/6/15

N2 - The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.

AB - The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.

UR - http://www.scopus.com/inward/record.url?scp=2942580749&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.02.071

DO - 10.1016/j.amjcard.2004.02.071

M3 - Article

AN - SCOPUS:2942580749

SN - 0002-9149

VL - 93

SP - 1558

EP - 1560

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 12

ER -

Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this